Intra-renal delivery of mesenchymal stem cells attenuates myocardial injury after reversal of hypertension in porcine renovascular disease

Stem Cell Research and Therapy

Volumn 6, Issue 1, 2015, Pages

  Eirin, Alfonso ^a   Zhu, Xiang Yang ^a   Ferguson, Christopher M ^a   Riester, Scott M ^a   Van Wijnen, Andre J ^a   Lerman, Amir ^a   Lerman, Lilach O ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; ISOPROSTANE DERIVATIVE; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL ISOLATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIASTOLE; EX VIVO STUDY; FEMALE; FIBROSIS; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART MUSCLE INJURY; HEART VENTRICLE REMODELING; HYPERTENSION; INFLAMMATION; KIDNEY FUNCTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OXIDATIVE STRESS; OXYGENATION; PIG; PRIORITY JOURNAL; RENOVASCULAR DISEASE; ANGIOPLASTY; ANIMAL; BLOOD; CARDIAC MUSCLE; CYTOLOGY; DIAGNOSTIC IMAGING; HEART; HEART INJURY; HEMODYNAMICS; HYPERTENSION, RENOVASCULAR; KIDNEY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MICROVASCULATURE; PATHOLOGY; PHYSIOLOGY; X-RAY COMPUTED TOMOGRAPHY;

SUIDAE; SUS;

ANGIOPLASTY; ANIMALS; BLOOD PRESSURE; COLLAGEN; CYTOKINES; FEMALE; FIBROSIS; GLOMERULAR FILTRATION RATE; HEART; HEART INJURIES; HEMODYNAMICS; HYPERTENSION, RENOVASCULAR; INFLAMMATION; ISOPROSTANES; KIDNEY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICROVESSELS; MYOCARDIUM; OXIDATIVE STRESS; SWINE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84928733348     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt541     Document Type: Article

References (50)

1. Green D, Kalra PA: The heart in atherosclerotic renovascular disease. Front Biosci (Elite Ed) 2012, 4:856-64.
2. Khangura KK, Eirin A, Kane GC, Misra S, Textor SC, Lerman A, et al.: Cardiac function in renovascular hypertensive patients with and without renal dysfunction. Am J Hypertens 2014, 27:445-53. 10.1093/ajh/hpt203
3. Murphy TP, Soares G, Kim M: Increase in utilization of percutaneous renal artery interventions by medicare beneficiaries, 1996-2000. AJR Am J Roentgenol 2004, 183:561-8. 10.2214/ajr.183.3.1830561
4. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, et al.: Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014, 370:13-22. 10.1056/NEJMoa1310753
5. Eirin A, Williams BJ, Ebrahimi B, Zhang X, Crane JA, Lerman A, et al.: Mitochondrial targeted peptides attenuate residual myocardial damage after reversal of experimental renovascular hypertension. J Hypertens 2014, 32:154-65. 10.1097/HJH.0b013e3283658a53
6. Urbieta-Caceres VH, Zhu XY, Jordan KL, Tang H, Textor K, Lerman A, et al.: Selective improvement in renal function preserved remote myocardial microvascular integrity and architecture in experimental renovascular disease. Atherosclerosis 2012, 221:350-8. 10.1016/j.atherosclerosis.2011.10.005
7. Kromer BM, Tippins JR: Coronary artery constriction by the isoprostane 8-epi prostaglandin f2 alpha. Br J Pharmacol 1996, 119:1276-80. 10.1111/j.1476-5381.1996.tb16033.x
8. Eirin A, Zhang X, Zhu XY, Tang H, Jordan KL, Grande JP, et al.: Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis. Nephrol Dial Transplant 2014, 29:274-82. 10.1093/ndt/gft305
9. Eirin A, Gloviczki ML, Tang H, Gossl M, Jordan KL, Woollard JR, et al.: Inflammatory and injury signals released from the post-stenotic human kidney. Eur Heart J 2013, 34:548a.
10. Eirin A, Zhu XY, Li Z, Ebrahimi B, Zhang X, Tang H, et al.: Endothelial outgrowth cells shift macrophage phenotype and improve kidney viability in swine renal artery stenosis. Arterioscler Thromb Vasc Biol 2013, 33:1006-13. 10.1161/ATVBAHA.113.301164
11. Saad A, Herrmann SM, Crane J, Glockner JF, McKusick MA, Misra S, et al.: Stent revascularization restores cortical blood flow and reverses tissue hypoxia in atherosclerotic renal artery stenosis but fails to reverse inflammatory pathways or glomerular filtration rate. Circ Cardiovasc Interv 2013, 6:428-35. 10.1161/CIRCINTERVENTIONS.113.000219
12. Lotfinegad P, Shamsasenjan K, Movassaghpour A, Majidi J, Baradaran B: Immunomodulatory nature and site specific affinity of mesenchymal stem cells: a hope in cell therapy. Adv Pharm Bull 2014, 4:5-13.
13. Reinders ME, Leuning DG, de Fijter JW, Hoogduijn MJ, Rabelink TJ: Mesenchymal stromal cell therapy for cardio renal disorders. Curr Pharm Des 2014, 20:2412-29. 10.2174/13816128113199990477
14. Karpov AA, Uspenskaya YK, Minasian SM, Puzanov MV, Dmitrieva RI, Bilibina AA, et al.: The effect of bone marrow- and adipose tissue-derived mesenchymal stem cell transplantation on myocardial remodelling in the rat model of ischaemic heart failure. Int J Exp Pathol 2013, 94:169-77.
15. Otto Beitnes J, Oie E, Shahdadfar A, Karlsen T, Muller RM, Aakhus S, et al.: Intramyocardial injections of human mesenchymal stem cells following acute myocardial infarction modulate scar formation and improve left ventricular function. Cell Transplant 2012, 21:1697-709. 10.3727/096368911X627462
16. Zhu XY, Urbieta-Caceres V, Krier JD, Textor SC, Lerman A, Lerman LO: Mesenchymal stem cells and endothelial progenitor cells decrease renal injury in experimental swine renal artery stenosis through different mechanisms. Stem Cells 2013, 31:117-25. 10.1002/stem.1263
17. Eirin A, Zhu XY, Krier JD, Tang H, Jordan KL, Grande JP, et al.: Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. Stem Cells 2012, 30:1030-41. 10.1002/stem.1047
18. Ebrahimi B, Eirin A, Li Z, Zhu XY, Zhang X, Lerman A, et al.: Mesenchymal stem cells improve medullary inflammation and fibrosis after revascularization of swine atherosclerotic renal artery stenosis. PLoS One 2013, 8:e67474. 10.1371/journal.pone.0067474
19. Zhu XY, Rodriguez-Porcel M, Bentley MD, Chade AR, Sica V, Napoli C, et al.: Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation 2004, 109:2109-15. 10.1161/01.CIR.0000125742.65841.8B
20. Chade AR, Zhu X, Mushin OP, Napoli C, Lerman A, Lerman LO: Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J 2006, 20:1706-8. 10.1096/fj.05-5680fje
21. Zhu XY, Chade AR, Rodriguez-Porcel M, Bentley MD, Ritman EL, Lerman A, et al.: Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol 2004, 24:1854-9. 10.1161/01.ATV.0000142443.52606.81
22. Zhu XY, Daghini E, Chade AR, Napoli C, Ritman EL, Lerman A, et al.: Simvastatin prevents coronary microvascular remodeling in renovascular hypertensive pigs. J Am Soc Nephrol 2007, 18:1209-17. 10.1681/ASN.2006090976
23. Eirin A, Ebrahimi B, Zhang X, Zhu XY, Tang H, Crane JA, et al.: Changes in glomerular filtration rate after renal revascularization correlate with microvascular hemodynamics and inflammation in swine renal artery stenosis. Circ Cardiovasc Interv 2012, 5:720-8. 10.1161/CIRCINTERVENTIONS.112.972596
24. Eirin A, Li Z, Zhang X, Krier JD, Woollard JR, Zhu XY, et al.: A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis. Hypertension 2012, 60:1242-9. 10.1161/HYPERTENSIONAHA.112.199919
25. Chade AR, Rodriguez-Porcel M, Grande JP, Krier JD, Lerman A, Romero JC, et al.: Distinct renal injury in early atherosclerosis and renovascular disease. Circulation 2002, 106:1165-71. 10.1161/01.CIR.0000027105.02327.48
26. Chade AR, Rodriguez-Porcel M, Grande JP, Zhu X, Sica V, Napoli C, et al.: Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. Arterioscler Thromb Vasc Biol 2003, 23:1295-301. 10.1161/01.ATV.0000077477.40824.52
27. Daghini E, Primak AN, Chade AR, Krier JD, Zhu XY, Ritman EL, et al.: Assessment of renal hemodynamics and function in pigs with 64-section multidetector CT: comparison with electron-beam CT. Radiology 2007, 243:405-12. 10.1148/radiol.2432060655
28. Rodriguez-Porcel M, Lerman A, Herrmann J, Schwartz RS, Sawamura T, Condorelli M, et al.: Hypertension exacerbates the effect of hypercholesterolemia on the myocardial microvasculature. Cardiovasc Res 2003, 58:213-21. 10.1016/S0008-6363(03)00250-5
29. Lin J, Zhu X, Chade AR, Jordan KL, Lavi R, Daghini E, et al.: Monocyte chemoattractant proteins mediate myocardial microvascular dysfunction in swine renovascular hypertension. Arterioscler Thromb Vasc Biol 2009, 29:1810-6. 10.1161/ATVBAHA.109.190546
30. Zhu XY, Daghini E, Chade AR, Rodriguez-Porcel M, Napoli C, Lerman A, et al.: Role of oxidative stress in remodeling of the myocardial microcirculation in hypertension. Arterioscler Thromb Vasc Biol 2006, 26:1746-52. 10.1161/01.ATV.0000227469.40826.01
31. Urbieta Caceres VH, Lin J, Zhu XY, Favreau FD, Gibson ME, Crane JA, et al.: Early experimental hypertension preserves the myocardial microvasculature but aggravates cardiac injury distal to chronic coronary artery obstruction. Am J Physiol Heart Circ Physiol 2011, 300:H693-701. 10.1152/ajpheart.00516.2010
32. Li ZL, Ebrahimi B, Zhang X, Eirin A, Woollard JR, Tang H, et al.: Obesity-metabolic derangement exacerbates cardiomyocyte loss distal to moderate coronary artery stenosis in pigs without affecting global cardiac function. Am J Physiol Heart Circ Physiol 2014, 306:H1087-101. 10.1152/ajpheart.00052.2013
33. Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M: Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 2006, 24:462-71. 10.1634/stemcells.2004-0331
34. Zhu XY, Daghini E, Chade AR, Lavi R, Napoli C, Lerman A, et al.: Disparate effects of simvastatin on angiogenesis during hypoxia and inflammation. Life Sci 2008, 83:801-9. 10.1016/j.lfs.2008.09.029
35. Chade AR, Zhu X, Lavi R, Krier JD, Pislaru S, Simari RD, et al.: Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation 2009, 119:547-57. 10.1161/CIRCULATIONAHA.108.788653
36. Chade AR, Rodriguez-Porcel M, Herrmann J, Zhu X, Grande JP, Napoli C, et al.: Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol 2004, 15:958-66. 10.1097/01.ASN.0000117774.83396.E9
37. Chade AR, Krier JD, Rodriguez-Porcel M, Breen JF, McKusick MA, Lerman A, et al.: Comparison of acute and chronic antioxidant interventions in experimental renovascular disease. Am J Physiol Renal Physiol 2004, 286:F1079-86. 10.1152/ajprenal.00385.2003
38. Pipinos II, Nypaver TJ, Moshin SK, Careterro OA, Beierwaltes WH: Response to angiotensin inhibition in rats with sustained renovascular hypertension correlates with response to removing renal artery stenosis. J Vasc Surg 1998, 28:167-77. 10.1016/S0741-5214(98)70212-5
39. Urbieta-Caceres VH, Zhu XY, Gibson ME, Favreau FD, Jordan K, Lerman A, et al.: Reversal of experimental renovascular hypertension restores coronary microvascular function and architecture. Am J Hypertens 2011, 24:458-65. 10.1038/ajh.2010.259
40. Khangura KK, Eirin A, Kane GC, Misra S, Textor SC, Lerman A, et al.: Extrarenal atherosclerotic disease blunts renal recovery in patients with renovascular hypertension. J Hypertens 2014, 32:1300-6. 10.1097/HJH.0000000000000160
41. Chong AY, Freestone B, Patel J, Lim HS, Hughes E, Blann AD, et al.: Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 2006, 97:671-5. 10.1016/j.amjcard.2005.09.113
42. Victorino GP, Newton CR, Curran B: Endothelin-1 decreases microvessel permeability after endothelial activation. J Trauma 2004, 56:832-6. 10.1097/01.TA.0000057228.45839.3C
43. Gueant-Rodriguez RM, Juilliere Y, Battaglia-Hsu SF, Debard R, Gerard P, Reyes P, et al.: Association of il1b polymorphism with left ventricular systolic dysfunction: A relation with the release of interleukin-1beta in stress condition. Pharmacogenet Genomics 2011, 21:579-86. 10.1097/FPC.0b013e3283493a05
44. Long CS: The role of interleukin-1 in the failing heart. Heart Fail Rev 2001, 6:81-94. 10.1023/A:1011428824771
45. Rizzi E, Ceron CS, Guimaraes DA, Prado CM, Rossi MA, Gerlach RF, et al.: Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and TGF-β in renovascular hypertension-induced cardiac hypertrophy. Exp Mol Pathol 2013, 94:1-9.
46. Schroecksnadel K, Frick B, Winkler C, Fuchs D: Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 2006, 4:205-13. 10.2174/157016106777698379
47. Mariappan N, Soorappan RN, Haque M, Sriramula S, Francis J: TNF-alpha-induced mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase mimetic Tempol. Am J Physiol Heart Circ Physiol 2007, 293:H2726-37. 10.1152/ajpheart.00376.2007
48. Brown JM, White CW, Terada LS, Grosso MA, Shanley PF, Mulvin DW, et al.: Interleukin 1 pretreatment decreases ischemia/reperfusion injury. Proc Natl Acad Sci U S A 1990, 87:5026-30. 10.1073/pnas.87.13.5026
49. Eirin A, Riester SM, Zhu XY, Tang H, Evans JM, O'Brien D, et al.: MicroRNA and mRNA cargo of extracellular vesicles from porcine adipose tissue-derived mesenchymal stem cells. Gene 2014, 551:55-64. 10.1016/j.gene.2014.08.041
50. Javazon EH, Beggs KJ, Flake AW: Mesenchymal stem cells: paradoxes of passaging. Exp Hematol 2004, 32:414-25. 10.1016/j.exphem.2004.02.004